<code id='6F394250CE'></code><style id='6F394250CE'></style>
    • <acronym id='6F394250CE'></acronym>
      <center id='6F394250CE'><center id='6F394250CE'><tfoot id='6F394250CE'></tfoot></center><abbr id='6F394250CE'><dir id='6F394250CE'><tfoot id='6F394250CE'></tfoot><noframes id='6F394250CE'>

    • <optgroup id='6F394250CE'><strike id='6F394250CE'><sup id='6F394250CE'></sup></strike><code id='6F394250CE'></code></optgroup>
        1. <b id='6F394250CE'><label id='6F394250CE'><select id='6F394250CE'><dt id='6F394250CE'><span id='6F394250CE'></span></dt></select></label></b><u id='6F394250CE'></u>
          <i id='6F394250CE'><strike id='6F394250CE'><tt id='6F394250CE'><pre id='6F394250CE'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:explore    Page View:6
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In